NMN
Status
No approved product. No FDA-approved drug labeling exists. The FDA has concluded NMN cannot lawfully be marketed as a dietary supplement in the United States because it was first authorized for investigation as a new drug, a position that remains under industry challenge.
What it is
An NAD precursor taken orally and studied for metabolic markers.
What published research measured
A nucleotide precursor to NAD, and the compound behind much of the interest in NAD-raising after mouse work reported metabolic and vascular improvements in aged animals. Human trials do exist and are better than for most of this category: several small randomized studies report NMN raises blood NAD concentrations reliably, and individual trials have reported modest improvements in aerobic capacity in amateur runners and in insulin sensitivity in prediabetic postmenopausal women. The gap is between raising a biomarker and changing an outcome — no trial has shown NMN alters any measure of ageing, disease incidence or survival in people. Its regulatory position in the United States changed materially when the FDA took the view that NMN is excluded from the dietary supplement definition because it had been authorized for investigation as a new drug.
Source
FDA position excluding NMN from the dietary supplement definition
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.